Live Breaking News & Updates on மைக்ரோ தலையீடு சாதனங்கள்

Stay updated with breaking news from மைக்ரோ தலையீடு சாதனங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Prosthetic Heart Valve Market to Witness Growth Acceleration During 2026


Prosthetic Heart Valve Market to Witness Growth Acceleration During 2026
Prosthetic Heart Valve Market to Witness Growth Acceleration During 2026
BriefingWire.com, 5/06/2021 -
Market Scenario
Global Prosthetic Heart Valve market is expected to reach USD 8,392 Bn by 2026 at a CAGR of 9.5 % during the forecast period.
The Global Prosthetic Heart Valve market is segmented based on type, end user region.
By Product type - transcatheter valve, tissue heart valves, mechanical valve.
By End User – Hospitals, Ambulatory Surgical Centers. By region - North America & South America, Europe, Asia-Pacific and, Middle East & Africa
The prosthetic heart valve is a medical device that implants in the heart disease patient who is suffering from heart failure. The mechanism of this device is that heart valve consists of orifices, which are provided blood flow. ....

United States , Labcor Laborat , Asia Pacific , Braile Biom , Boston Scientific Corporation , Commonwealth Edison Company , Lepu Medical Technology Beijing Co Ltd , Life Technologies Inc , Edwards Lifesciences Corporation , Cryolife Inc , Interventional Devices Inc , Dimensions Inc , Sadra Medical Inc , Cardiosolutions Inc , Technology Est , Jenavalve Technology Inc , Mitralsolutions Inc , Surgical Centers , Jude Medical Inc , Edwards Lifesciences , Valvexchange Inc , Heart Valve Market , Witness Growth Acceleration During , Prosthetic Heart Valve , Report Sample , Global Prosthetic Heart Valve ,

Micro Interventional Devices, Inc.™ Announces Submission of CE Mark Technical Documentation for the MIA-T™ Percutaneous Tricuspid Annuloplasty System


Share this article
NEWTOWN, Pa., Jan. 28, 2021 /PRNewswire/
Micro Interventional Devices, Inc.™ (MID) announced today that it has submitted the required technical documentation for CE Mark approval for its MIA-T™ Percutaneous Tricuspid Annuloplasty System for tricuspid valve repair to its Notified Body. The receipt of a CE Mark would allow MID to commercialize MIA-T in the European Union in countries governed by the European Medical Device Regulations (MDR).  MID is anticipating an approval in 2021.  This will enable a treatment option for millions of patients currently at too high a risk to be treated with the standard of care, open surgical repair with cardiopulmonary bypass. ....

United States , Katherine Whitman , Michael Whitman , Willard Hennemann , European Union , Company Contact , Interventional Devices Inc , Interventional Devices , Percutaneous Tricuspid Annuloplasty System , European Medical Device Regulations , Transcatheter Tricuspid Annular Repair , Device Regulation , Micro Interventional Devices , Transcatheter Cardiac Repair , ஒன்றுபட்டது மாநிலங்களில் , க்யாதரிந் விட்மேன் , மைக்கேல் விட்மேன் , ஐரோப்பிய தொழிற்சங்கம் , நிறுவனம் தொடர்பு , தலையீடு சாதனங்கள் இன்க் , தலையீடு சாதனங்கள் , ஐரோப்பிய மருத்துவ சாதனம் ஒழுங்குமுறைகள் , சாதனம் ஒழுங்குமுறை , மைக்ரோ தலையீடு சாதனங்கள் ,